Chemotherapy Response and Disease Progression in Melanoma
Author Information
Author(s): H. Joensuu
Primary Institution: Turku University Central Hospital
Hypothesis
Patients with an objective response to DTIC-CCNU therapy have melanoma with a slow progression rate.
Conclusion
Patients who responded to chemotherapy lived longer than those who did not, suggesting that the nature of their tumors may be less aggressive.
Supporting Evidence
- Patients with an objective response had a median survival time of 25 months.
- Only 5% of patients had a complete response, while 11% had a partial response.
- Responding patients had a longer time from diagnosis to distant metastases.
Takeaway
This study found that patients with melanoma who responded to chemotherapy lived longer, but it might be because their cancer grows slower.
Methodology
Retrospective analysis of 55 patients treated with DTIC and CCNU, assessing response and progression rates.
Potential Biases
Potential bias due to nonrandomized treatment and selection of patients.
Limitations
The study is retrospective and lacks randomization.
Participant Demographics
30 males and 25 females, mean age 52 years, range 21 to 72 years.
Statistical Information
P-Value
P = 0.0006
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website